Search the Newsreel

Armistice Capital (CALC) discloses 3.41M-share, 9.99% holding in CalciMedica

Armistice Capital, LLC and Steven Boyd have reported a significant holding in CalciMedica, Inc., disclosing beneficial ownership of 3,411,361 shares, which represents 9.99% of the company's common stock. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as …

Chimera Investment (CIM) Dividend Yield 2026 & History $CIM

Robert Keane Sells 6,500 Shares of Cimpress (NASDAQ:CMPR) Stock

Cimpress CEO Robert Keane sold 6,500 shares of the company's stock for $624,585, reducing his direct ownership by 7.86%. The company recently reported quarterly EPS below consensus, though revenue was in line with expectations. Analysts generally maintain a "Buy" rating with a consensus price …

Cimpress Insider Sold Shares Worth $624,611, According to a Recent SEC Filing

A recent SEC filing revealed that an insider at Cimpress (CMPR) sold shares valued at $624,611. This transaction occurred amidst other company news, including an analyst price target adjustment and recent quarterly earnings reports. Cimpress, a company focused on mass customization of printing and …

CalciMedica shares see H.C. Wainwright neutral rating reiterated

H.C. Wainwright has reiterated a Neutral rating on CalciMedica (NASDAQ:CALC) following the company's second-quarter financial results. The company reported a wider-than-expected loss of $0.45 per share for Q2 2026 and ended the quarter with $18.6 million in cash, which is expected to fund operations …

Price to book forward of CalciMedica, Inc. – BOATS:CALC

The article provides a financial data point for CalciMedica, Inc. (CALC) related to its "Price to book forward" metric. It appears to be a stub or partial financial report from TradingView, indicating the company's market status and some basic financial information without further details …

Cimpress PLC (CMPR) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 77/100

Cimpress PLC (CMPR) saw its stock rise 3.4% to $98.64, marking a 68.8% increase over the past year. Despite this growth and a GF Score of 77/100, GuruFocus's GF Value™ indicates the stock is 14.6% overvalued, suggesting it trades above its intrinsic value. Insider …

CalciMedica Releases Q2 2026 Financial Results

CalciMedica (CALC) reported a wider net loss of $7.7M, or $0.45 per share, for Q2 2026, an increase from $0.40 per share in Q2 2025. This reflects continued investment in its biopharmaceutical pipeline and the capital-intensive nature of clinical-stage development. Despite the losses, analyst …

Chimera Investment (CIM) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Tyra Walton President and Chief Executive Officer - Phillip Kardis Chief Financial Officer - Subramaniam Viswanathan Chief Investment Officer - Jack Macdowell President …

Cimpress to Present at the 17th Annual Midwest Ideas Conference on August 26, 2026, in Chicago

Cimpress plc announced that its Executive Vice President and Chief Financial Officer, Sean Quinn, will present at the 17th Annual Midwest Ideas Conference on August 26, 2026. The 35-minute presentation will be webcast and available on the Cimpress Investor Relations website, with a replay …

Wasatch Advisors LP Invests $47.55 Million in Cimpress plc $CMPR

Wasatch Advisors LP has acquired a new position in Cimpress plc (NASDAQ:CMPR), purchasing 467,499 shares valued at approximately $47.55 million, making them owners of about 1.93% of the company. Other institutional investors like Amundi, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., Legal & General Group …

CIMPRESS plc SEC Filing (Aug 11, 2026)

CIMPRESS plc (CMPR) filed a Form 144 with the SEC on August 11, 2026, indicating a proposed sale of 6,500 common shares by an insider for an aggregate market value of $619,970. The shares were acquired on August 15, 2024, as compensation in the …

Cimpress plc (CMPR) awards performance share units to CEO and chairman

Cimpress plc announced that its CEO and Chairman, Robert S. Keane, has been awarded two performance share unit (PSU) grants tied to the company's fiscal year 2026 performance. These awards, totaling 121,503 PSUs for his CEO role and 3,115 PSUs for his director role, …

CalciMedica, Inc. 2Q 2026: Net loss $7.7M, EPS $(0.45) — 10-Q Summary

CalciMedica, Inc. reported a net loss of $7.7 million for the second quarter of 2026, an increase from the $6.0 million loss in the prior year, with diluted loss per share at $(0.45). The company's clinical development is focused on Auxora and CM5480, with …

Barrington Research Adjusts Cimpress PT to $121 From $113, Maintains Outperform Rating

Barrington Research has increased its price target for Cimpress plc (CMPR) to $121 from $113, while reiterating an Outperform rating on the stock. This adjustment reflects a positive outlook on the company's future performance. The article also lists recent news and financial activities related …

CalciMedica Q2 FY26 net loss widens to $7.65 million

CalciMedica reported a widened net loss of $7.65 million for Q2 FY26, up from $5.96 million in the prior year, with loss per share increasing to $0.45. Despite this, the company saw a significant reduction in R&D and G&A expenses and increased its cash …

CalciMedica stock gains 6% despite earnings miss on pulmonary trial

CalciMedica (NASDAQ:CALC) reported a second-quarter loss of $0.45 per share, missing analyst estimates, yet its stock rose 6.22% in pre-market trading. The increase was driven by investor focus on the company's advances in its pulmonary hypertension program and regulatory progress, including FDA alignment for …

CalciMedica GAAP EPS of -$0.45 misses by $0.16

* CalciMedica press release [https://seekingalpha.com/pr/20614225-calcimedica-reports-second-quarter-2026-financial-results-and-provides-clinical-and-corporate] (CALC [https://seekingalpha.com/symbol/CALC]): Q2 GAAP EPS of -$0.45 misses by $0.16. * Cash Position: Cash and cash equivalents were $18.6 million as of June 30, 2026. The Company expects its cash and cash equivalents to fund its current operating plan …

Merlin Properties: nuestra opinión sobre la acción tras la publicación de resultados

Chimera Investment (CIM) Posted A First Half Loss, Is The Undervalued Case Still Convincing?

Will Weaker 2026 Profitability and Completed Buybacks Change Chimera Investment's (CIM) Capital Allocation Narrative?

In the second quarter of 2026, Chimera Investment Corporation reported net income of US$17.37 million and a basic loss per share from continuing operations of US$0.05, while also declaring third-quarter cash dividends on all four series of its preferred stock and confirming completion of …

Cimpress (CMPR) Stock Profit Rebound Meets A Tough Cash Flow Question

CIMB (1023.KL) Q4 FY2025 earnings call transcript

Cimpress PLC (CMPR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cimpress PLC (CMPR) has an earnings forecast score of 9.00, ranking 4th in the Professional & Commercial Services industry. Analysts maintain a "Strong Buy" rating with a target price of $86.50, suggesting a potential upside of 7.54%. The company's expected revenue for the next …

CalciMedica Inc expected to post a loss of 28 cents a share - Earnings Preview

CalciMedica Inc is projected to report a loss of 28 cents per share, according to this earnings preview. The information was sourced from Refinitiv and distributed via Reuters. Readers can access the full article through TradingView.

Cimpress (CMPR) Q4 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations and Sustainability - Meredith BurnsFounder, Chairman and Chief Executive Officer - Robert KeaneExecutive Vice President and Chief Financial Officer - Sean Quinn TAKEAWAYS …

Cimpress FY 2026: Revenue $3.74B, EPS $3.79— 10-K Summary

Cimpress (CMPR) reported strong financial results for full-year 2026, with revenue reaching $3.74 billion and diluted EPS at $3.79, reflecting a significant year-over-year improvement. The company's net income soared to $95.87 million, driven by product mix gains and strategic operational investments. Growth was primarily …

CIMB Niaga and Ajaib Collaborate to Integrate Banking and Investment Services

CalciMedica Inc (CALC) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for CalciMedica Inc (CALC), highlighting analyst ratings, target prices, and historical EPS performance. Analysts currently have a "Buy" consensus for CALC, with a target price of USD 15.50 and a significant upside potential of +1374.72%. The previous quarter's …

How Investors May Respond To Chimera Investment (CIM) Weaker Earnings And Maintained Preferred Dividends

Chimera Investment (CIM) Stock Sinks As Book Value Decline Undercuts Dividend Appeal

Chimera Investment Corp (CIM) (Q2 2026) Earnings Call Highlights: EAD Beats Dividend Amid ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Chimera Investment Corp (NYSE:CIM) generated $0.46 of EAD per share in Q2 2026, exceeding its …

Earnings call transcript: Chimera Investment misses Q2 2026 estimates as shares fall premarket By Investing.com